| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 28 | 54.8x | 17.8x | Bottom tier | |
Growth | 27 | 3.7% | 7.1% | Bottom tier | |
Quality | 51 | 8.5% | 4.5% | Around median | |
Safety | 75 | 0.9x | 2.6x | Top tier | |
Capital Return | 35 | 0.86% | 2.12% | Bottom tier | |
Momentum | 73 | 4.8% | 2.9% | Top tier | |
Sentiment | 82 | 11 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Corteva operates in agricultural technology through two main businesses: Seed and Crop Protection. The Seed business generates revenue from the sale of seeds, traits, and licenses, benefiting from demand for the latest genetic combinations and products such as Pioneer, Brevant, and Conkesta E3; Crop Protection sells herbicides, insecticides, fungicides, and biological products, with an increasing focus on differentiated and new products. In the first half of fiscal year 2026, the Seed business delivered organic growth across all regions, while Crop Protection benefited from volume growth in new products despite competitive pricing pressure.
In quarter 2 of fiscal year 2026, revenue reached $6.4 billion and gross profit reached $3.7 billion, equivalent to a gross margin of approximately 57.8%, while net income was $1.2 billion and earnings per share were $1.73. Operating EBITDA reached $2.3 billion, up 4% year over year. For the first half of fiscal year 2026, net sales increased 4% to $11.3 billion, organic sales grew 2%, and operating EBITDA reached $3.7 billion, up 10%, with the margin expanding by approximately 200 basis points to 32.8%.
The improvement in the first half of fiscal year 2026 came from a specific mix: price and mix added approximately $100 million, volume about $40 million, cost reductions and productivity improvements more than $160 million, currency approximately $85 million, and improved net seed licensing returns $90 million. This contribution shows that earnings growth did not depend on sales alone, but also on seed pricing, licensing, manufacturing efficiency, and lower input costs, while Crop Protection pricing remained under pressure.
The average analyst price target is $95.38, within a range of $86 to $103, with a consensus rating of “Buy”; the average is approximately 4.8% above the 52-week range high of $90.97, while the lowest target is within the 52-week range of $60.535–$90.97. The data do not include a usable price-to-earnings ratio, so the valuation of CTVA here is based on the target range and the expansion of its operating results, balancing the raised fiscal year 2026 outlook against Crop Protection pricing pressure and execution risks related to the Vylor separation.
Figures in the text are as of 2026-08-27; the live price is shown at the top of the page.
Revenue in quarter 2 of fiscal year 2026 reached approximately $6.4 billion, gross profit was $3.7 billion, and net income was $1.2 billion. Operating EBITDA increased 4% to $2.3 billion. Support came from seed pricing, productivity, licensing, and lower input costs, while growth in new products partially offset Crop Protection pricing pressure.
On July 31, 2026, the company raised its operating EBITDA range to $4.1–$4.3 billion. It also raised expected operating earnings per share to $3.60–$3.80 and the operating earnings margin to 22.5%–23.5%. At the midpoints, the outlook equates to growth of approximately 9% in operating EBITDA and 11% in earnings per share compared with the previous fiscal year.
The Seed business delivered organic growth across all regions during the first half of fiscal year 2026, led by North America and the Europe, Middle East, and Africa region. Improved net licensing returns contributed $90 million, with the licensing business approximately three years ahead of the original plan. The company also recorded a modest corn share gain through Pioneer and Brevant, and expects Conkesta E3 penetration to reach a high-single-digit or low-double-digit percentage in fiscal year 2027.
Automated analysis for informational purposes only — not investment advice.
Crop Protection prices declined by a low-single-digit percentage in the first half of fiscal year 2026, approximately 3% according to management. The company expects prices to decline by a low- to mid-single-digit percentage in the second half, with greater pressure in Brazil and competition from generic products following the expiration of some patents. In contrast, revenue from new products is approaching $2 billion during fiscal year 2026, and their prices remained nearly stable while volumes grew at a high-single-digit rate.
The company is targeting completion of the separation on October 1, 2026, with Vylor beginning operations as an independent public company focused on advanced seeds and genetics. As of July 31, 2026, Corteva had publicly filed Form 10, appointed both boards of directors, and announced Luke Kism as Chief Executive Officer of New Corteva, while capital structures and the separation of information technology remained among the required work. Management estimated the remaining impact from lost integration benefits at approximately $25 million during fiscal year 2026, down from a previous estimate of $100 million.
The average analyst price target is $95.38, with a high target of $103 and a low target of $86, and a consensus rating of “Buy.” The average target exceeds the 52-week range high of $90.97 by approximately 4.8%, while the low target remains within the $60.535–$90.97 range. The data do not present a usable price-to-earnings ratio, so the target range should be considered alongside the raised fiscal year 2026 outlook, pricing pressure, and the operational separation.
